Fusion Fund

Blumind develops an analog AI neural network architecture designed for low-power edge computing and provides inferencing engines for edge smart sensors and devices. The platform uses standard semiconductor technology to deliver real-time inference with minimal energy consumption, enabling always-on artificial intelligence at the edge. It supports features such as keyword detection, biometric pattern recognition, gesture identification, and image classification, allowing industries to deploy efficient AI on edge devices.

Proscia Inc., established in 2014 and headquartered in Philadelphia, Pennsylvania, specializes in digital pathology informatics through its innovative cloud-based platform. This platform aids in routine pathology operations, enhances cancer diagnosis, and seeks to improve patient outcomes. By leveraging advanced computing technologies, Proscia's solution unlocks hidden data that is not discernible to the human eye, transforming that information into valuable insights. These insights support physicians in accelerating the development of life-saving medical advances, ultimately contributing to a more effective diagnostic process in the field of pathology.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Proscia Inc., established in 2014 and headquartered in Philadelphia, Pennsylvania, specializes in digital pathology informatics through its innovative cloud-based platform. This platform aids in routine pathology operations, enhances cancer diagnosis, and seeks to improve patient outcomes. By leveraging advanced computing technologies, Proscia's solution unlocks hidden data that is not discernible to the human eye, transforming that information into valuable insights. These insights support physicians in accelerating the development of life-saving medical advances, ultimately contributing to a more effective diagnostic process in the field of pathology.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Proscia Inc., established in 2014 and headquartered in Philadelphia, Pennsylvania, specializes in digital pathology informatics through its innovative cloud-based platform. This platform aids in routine pathology operations, enhances cancer diagnosis, and seeks to improve patient outcomes. By leveraging advanced computing technologies, Proscia's solution unlocks hidden data that is not discernible to the human eye, transforming that information into valuable insights. These insights support physicians in accelerating the development of life-saving medical advances, ultimately contributing to a more effective diagnostic process in the field of pathology.

Founded in 2012, nView Medical specializes in developing and manufacturing medical imaging equipment for invasive surgical procedures. Its flagship product, nView s1, offers real-time 3D visualization using artificial intelligence and model-based imaging, enhancing surgical accuracy and efficiency.

Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.

Sonavex develops imaging technologies for vascular and surgical care, employing ultrasound to detect postoperative blood clots at the point of care and to measure intravascular flow metrics for timely decision making. It also develops bioresorbable, echogenic devices to mark at-risk vessels and to collect data on arteriovenous fistula flow, diameter, and depth at dialysis clinics to assess maturation and anticipate future complications. Based in Baltimore, Maryland, Sonavex focuses on delivering data-driven visualization of vessel health to improve surgical and dialysis patient outcomes.